Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACTUNASDAQ:NKTXNYSE:OSTXNASDAQ:SCPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACTUActuate Therapeutics$7.22+4.5%$7.79$5.51▼$11.73$141.02MN/A44,692 shs59,372 shsNKTXNkarta$1.71-10.5%$1.94$1.31▼$10.16$135.53M0.831.09 million shs1.09 million shsOSTXOS Therapies$1.54+2.0%$1.80$1.33▼$7.00$33.52MN/A506,543 shs357,045 shsSCPHscPharmaceuticals$2.30-8.0%$3.17$2.20▼$5.65$115.65M0.38340,335 shs397,852 shsUnlock the Potential in Options TradingOptions trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACTUActuate Therapeutics+4.49%-4.75%+2.85%-13.33%+721,999,900.00%NKTXNkarta-10.47%-13.20%+3.64%-31.60%-81.97%OSTXOS Therapies+1.99%-4.94%+1.99%-63.85%+153,999,900.00%SCPHscPharmaceuticals-8.00%-24.34%-30.09%-35.93%-55.85%Remove AdsCompare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationACTUActuate TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ANKTXNkarta2.5497 of 5 stars3.62.00.00.02.52.50.6OSTXOS Therapies1.9035 of 5 stars3.70.00.00.01.11.70.6SCPHscPharmaceuticals3.3974 of 5 stars3.52.00.04.20.01.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACTUActuate Therapeutics 3.00Buy$20.00177.01% UpsideNKTXNkarta 3.25Buy$14.86768.84% UpsideOSTXOS Therapies 3.40Buy$18.001,068.83% UpsideSCPHscPharmaceuticals 3.00Buy$14.00508.70% UpsideCurrent Analyst Ratings BreakdownLatest OSTX, SCPH, ACTU, and NKTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/2/2025OSTXOS TherapiesLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$19.003/31/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.003/27/2025NKTXNkartaStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$15.00 ➝ $14.003/27/2025NKTXNkartaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.003/27/2025NKTXNkartaNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$11.00 ➝ $11.003/20/2025SCPHscPharmaceuticalsMaxim GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$20.00 ➝ $12.003/20/2025SCPHscPharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.003/17/2025ACTUActuate TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$20.003/3/2025SCPHscPharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$18.00 ➝ $18.002/20/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.001/30/2025OSTXOS TherapiesD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$20.00 ➝ $20.00(Data available from 4/4/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACTUActuate TherapeuticsN/AN/AN/AN/AN/AN/ANKTXNkartaN/AN/AN/AN/A$5.56 per shareN/AOSTXOS TherapiesN/AN/AN/AN/AN/AN/ASCPHscPharmaceuticals$36.33M3.18N/AN/A$1.04 per share2.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACTUActuate Therapeutics-$24.75MN/A0.00∞N/AN/AN/AN/AN/ANKTXNkarta-$117.50M-$1.66N/AN/AN/AN/A-27.13%-21.67%5/8/2025 (Estimated)OSTXOS Therapies-$7.79MN/A0.00N/AN/AN/AN/A-569.57%N/ASCPHscPharmaceuticals-$54.81M-$1.90N/AN/AN/A-264.60%-244.93%-68.56%5/13/2025 (Estimated)Latest OSTX, SCPH, ACTU, and NKTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/26/2025Q4 2024NKTXNkarta-$0.41-$0.35+$0.06-$0.35N/AN/A3/19/2025Q4 2024SCPHscPharmaceuticals-$0.40-$0.35+$0.05-$0.35$12.08 million$12.15 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACTUActuate TherapeuticsN/AN/AN/AN/AN/ANKTXNkartaN/AN/AN/AN/AN/AOSTXOS TherapiesN/AN/AN/AN/AN/ASCPHscPharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACTUActuate TherapeuticsN/A1.681.68NKTXNkartaN/A12.9112.91OSTXOS TherapiesN/A0.760.76SCPHscPharmaceuticals1.668.086.89Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACTUActuate TherapeuticsN/ANKTXNkarta80.54%OSTXOS TherapiesN/ASCPHscPharmaceuticals89.52%Insider OwnershipCompanyInsider OwnershipACTUActuate TherapeuticsN/ANKTXNkarta8.70%OSTXOS Therapies13.80%SCPHscPharmaceuticals5.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACTUActuate Therapeutics1019.53 millionN/AN/ANKTXNkarta14070.96 million64.43 millionOptionableOSTXOS TherapiesN/A21.77 millionN/AN/ASCPHscPharmaceuticals3050.28 million47.28 millionOptionableOSTX, SCPH, ACTU, and NKTX HeadlinesRecent News About These CompaniesWhy scPharmaceuticals Inc.’s (SCPH) Stock Is Down 11.41%April 2 at 11:54 AM | aaii.comCraig-Hallum Sticks to Its Buy Rating for scPharmaceuticals (SCPH)March 22, 2025 | markets.businessinsider.comscPharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results with Major FDA Approval for FUROSCIXMarch 22, 2025 | nasdaq.comscPharmaceuticals (NASDAQ:SCPH) Given New $12.00 Price Target at Maxim GroupMarch 21, 2025 | marketbeat.comscPharmaceuticals Full Year 2024 Earnings: In Line With ExpectationsMarch 21, 2025 | finance.yahoo.comHC Wainwright Reiterates "Buy" Rating for scPharmaceuticals (NASDAQ:SCPH)March 21, 2025 | marketbeat.comscPharmaceuticals price target lowered to $12 from $20 at MaximMarch 21, 2025 | markets.businessinsider.comscPharmaceuticals (NASDAQ:SCPH) Issues Earnings ResultsMarch 20, 2025 | marketbeat.comscPharmaceuticals (NASDAQ:SCPH) Announces Quarterly Earnings ResultsMarch 20, 2025 | marketbeat.comQ4 2024 scPharmaceuticals Inc Earnings CallMarch 20, 2025 | finance.yahoo.comscPharmaceuticals reports Q 4EPS (35c), consensus (39c)March 20, 2025 | markets.businessinsider.comscPharmaceuticals Inc. (SCPH) Q4 2024 Earnings Call TranscriptMarch 19, 2025 | seekingalpha.comScPharmaceuticals outlines FUROSCIX expansion strategy with CKD launch in April 2025March 19, 2025 | msn.comScPharmaceuticals, Inc. (SCPH) Reports Q4 Loss, Tops Revenue EstimatesMarch 19, 2025 | zacks.comscPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides ...March 19, 2025 | gurufocus.comscPharmaceuticals Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateMarch 19, 2025 | globenewswire.comscPharmaceuticals to Announce Fourth Quarter and Full Year 2024 Financial Results on Wednesday, March 19, 2025March 12, 2025 | globenewswire.comKing Luther Capital Management Corp Buys 632,120 Shares of scPharmaceuticals Inc. (NASDAQ:SCPH)March 12, 2025 | marketbeat.comThe week in pharma: action, reaction and insight – week to March 7March 9, 2025 | thepharmaletter.comWearable Furosemide Delivery System Approved for CKD PatientsMarch 7, 2025 | empr.comFDA nod for scPharmaceuticals’ Furoscix sNDAMarch 7, 2025 | thepharmaletter.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy Archer Aviation Stock Could Soar After Palantir PartnershipBy Jeffrey Neal Johnson | March 20, 2025View Why Archer Aviation Stock Could Soar After Palantir PartnershipIntel Foundry’s Moment of Truth: Will 18A Deliver?By Jeffrey Neal Johnson | March 6, 2025View Intel Foundry’s Moment of Truth: Will 18A Deliver?Taiwan Semiconductor’s Huge U.S. Move—Stock Impact AheadBy Leo Miller | March 15, 2025View Taiwan Semiconductor’s Huge U.S. Move—Stock Impact AheadSouthwest Airlines Could Triple From Here—Here's HowBy Gabriel Osorio-Mazilli | March 18, 2025View Southwest Airlines Could Triple From Here—Here's How 3 Companies Buying Back Stock—Why It MattersBy Gabriel Osorio-Mazilli | March 12, 2025View 3 Companies Buying Back Stock—Why It MattersOSTX, SCPH, ACTU, and NKTX Company DescriptionsActuate Therapeutics NASDAQ:ACTU$7.22 +0.31 (+4.49%) Closing price 04/3/2025 03:59 PM EasternExtended Trading$7.00 -0.22 (-3.05%) As of 04:24 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.Nkarta NASDAQ:NKTX$1.71 -0.20 (-10.47%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$1.72 +0.02 (+0.88%) As of 05:37 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. The company's lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen that is in Phase 1 clinical trial for the treatment of relapsed/refractory (r/r) non-hodgkin lymphoma, as well as for lupus nephritis. It also develops NKX101, a CAR NK product candidate targeting cells that display NKG2D ligands, which is in Phase I clinical trial for the treatment of r/r acute myeloid leukemia or higher risk myelodysplastic syndromes, as well as for solid tumors. In addition, the company develops NKX070, targeting the CD70 tumor antigen to treat solid and liquid tumors; and NK+T cell therapy for use in the treatment of oncology, autoimmune disease, or infectious disease. It has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.OS Therapies NYSE:OSTX$1.54 +0.03 (+1.99%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$1.62 +0.08 (+5.26%) As of 06:11 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.OS Therapies Incorporated, a clinical stage biopharmaceutical company, focuses on the identification, development, and commercialization of treatments for osteosarcoma and other solid tumors in the United States. Its pipeline includes OST-HER2, an off-the-shelf immunotherapy for osteosarcoma patients; and OST-tunable drug conjugate (OST-tADC), an antibody-drug conjugate technology, with a plug-and-play platform that features tunable pH sensitive silicone linkers. OS Therapies Incorporated was incorporated in 2018 and is based in Rockville, Maryland.scPharmaceuticals NASDAQ:SCPH$2.30 -0.20 (-8.00%) Closing price 04/3/2025 04:00 PM EasternExtended Trading$2.32 +0.02 (+0.83%) As of 04/3/2025 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom’s VMware Strategy Could Fuel the Next AVGO Rally Cathie Wood Loads Up on Baidu—Is It the Right Time to Buy? Celsius Heats Up: Acquisition, Analyst Upgrade Fuel Momentum 5 Reasons Why Halliburton Is a Good Buy in 2025 First Watch Restaurant Group: A First-Rate Small-Cap Growth Stock Tesla Stock: What To Expect With Their Delivery Numbers Report Rocket Lab: $5.6 Billion Defense Contract Fuels RKLB’s Future Equinix: A Smart Bet on Data Centers, Dividends, and AI Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
